Evidence map›Paper›PMID 40292966›Full record

ArticleSensors (Basel, Switzerland)2025

Multi-Scale Convolutional Attention and Structural Re-Parameterized Residual-Based 3D U-Net for Liver and Liver Tumor Segmentation from CT.

Ziwei Song, Weiwei Wu, Shuicai Wu

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ziwei SongDepartment of Biomedical Engineering, College of Chemistry and Life Sciences, Beijing University of Technology, Beijing 100124, China.ORCID 0009-0000-8178-1264
Weiwei WuCollege of Biomedical Engineering, Capital Medical University, Beijing 100069, China.
Shuicai WuDepartment of Biomedical Engineering, College of Chemistry and Life Sciences, Beijing University of Technology, Beijing 100124, China.

Funding

National Natural Science Foundation of China Number 61801312R&D Program of the Beijing Municipal Education Commission KM202310025019
6 · The paper itself

Abstract

Accurate segmentation of the liver and liver tumors is crucial for clinical diagnosis and treatment. However, the task poses significant challenges due to the complex morphology of tumors, indistinct features of small targets, and the similarity in grayscale values between the liver and surrounding organs. To address these issues, this paper proposes an enhanced 3D UNet architecture, named ELANRes-MSCA-UNet. By incorporating a structural re-parameterized residual module (ELANRes) and a multi-scale convolutional attention module (MSCA), the network significantly improves feature extraction and boundary optimization, particularly excelling in segmenting small targets. Additionally, a two-stage strategy is employed, where the liver region is segmented first, followed by the fine-grained segmentation of tumors, effectively reducing false positive rates. Experiments conducted on the LiTS2017 dataset demonstrate that the ELANRes-MSCA-UNet achieved Dice scores of 97.2% and 72.9% for liver and tumor segmentation tasks, respectively, significantly outperforming other state-of-the-art methods. These results validate the accuracy and robustness of the proposed method in medical image segmentation and highlight its potential for clinical applications.

Indexed as

Image Processing, Computer-AssistedImaging, Three-DimensionalLiverLiver NeoplasmsTomography, X-Ray ComputedAlgorithmsHumansNeural Networks, Computer3D UNetliver and tumor segmentationmulti-feature extractionmulti-scale convolutional attentionstructural re-parameterization

Identifiers

PMID40292966
PMCPMC11946428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.